

Dr. Reddys(RDY)

\$68.55 (As of 09/28/20)

Price Target (6-12 Months): **\$73.00**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 05/15/20)

Prior Recommendation: Outperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

2-Buy

Zacks Style Scores:

VGM:C

Value: C


Growth: B

Momentum: D

Summary

In first-quarter fiscal 2021, Dr. Reddy's top line recorded year-over-year growth while the bottom line fell year over year. While sales volume was affected in some of the company's markets due to lower prescriptions generated and a fall in patient footfalls in pharmacies/clinics due to COVID-19, the pricing environment was relatively stable, new product launches continued and depreciation of rupee against the U.S. dollar and Euro supported the business. As of Jun 30, the company had 101 generic filings (99 abbreviated New Drug Applications and two new drug applications) pending FDA approval. Approval of new generics should further bolster the portfolio. The company is divesting non-core assets to channelize its sources to increase profitability. However, generic competition remains a concern for the company.


Price, Consensus & Surprise



Data Overview

52-Week High-Low	\$73.50 - \$33.33
20-Day Average Volume (Shares)	192,199
Market Cap	\$11.4 B
Year-To-Date Price Change	70.1%
Beta	0.51
Dividend / Dividend Yield	\$0.27 / 0.4%
Industry	Medical - Generic Drugs
Zacks Industry Rank	Bottom 12% (219 out of 250)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	NA
Last Sales Surprise	NA
EPS F1 Estimate 4-Week Change	-1.3%
Expected Report Date	11/06/2020
Earnings ESP	0.0%
P/E TTM	28.8
P/E F1	36.1
PEG F1	NA
P/S TTM	4.6

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2022					2,741 E
2021	585 A				2,488 E
2020	558 A	680 A	614 A	588 A	2,316 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2022					\$2.25 E
2021	\$0.46 A				\$1.90 E
2020	\$0.58 A	\$0.93 A	\$0.40 A	\$0.61 A	\$2.79 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 09/28/2020. The reports text is as of 09/29/2020.

Overview

India-based Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984.

The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments:


- **Global Generics** – This segment consists of branded and unbranded prescription drugs along with over-the-counter (OTC) drugs. It includes the operations of the company's biologics business.
- **Pharmaceutical Services & Active Ingredients (PSAI)** – This segment is composed of active pharmaceutical ingredients (API) and custom pharmaceutical services.
- **Proprietary Products and Others** – This segment involves the new chemical entities, the differentiated formulations business and a dermatology specialty business.

Global Generics contributed 79%, PSAI contributed 15% and Proprietary Products and Others contributed 5% and others contributed 1% to total revenues in fiscal 2020.

The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.

Dr. Reddy's reported fiscal 2020 (ending Mar 31, 2020) revenues of \$2.3 billion.

As of Mar 31, 2020, the company had 99 generic filings (97 abbreviated New Drug Applications [ANDAs] and two new drug applications) pending FDA approval. Of these 99 ANDAs, 54 were Para IV filings and 30 have first-to-file status. New product launches, especially complex generics, should help drive the generics business over regular intervals.



Source: Zacks Investment Research

Reasons To Buy:

▲ **Strong Generic Pipeline:** Dr. Reddy's enjoys a strong position in the generics market. As of Jun 30, 2020, the company had 101 generic filings (99 abbreviated New Drug Applications [ANDAs] and two new drug applications) pending FDA approval. Of these 99 ANDAs, 54 were Para IV filings and 28 have first-to-file status. New product launches, especially complex generics, should help drive the generics business over regular intervals. In the first quarter of 2020, the company launched six products in North America, including fenofibrate tablets, nitroglycerin Patch, amphetamine sulfate tablets, desmopressin acetate ampules, colchicine tablets and abiraterone acetate tablets.

In April 2019, Dr. Reddy's entered a definitive agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed ANDAs in the United States. The portfolio includes more than 30 generic injectable products. These products will be technology transferred and ready for launch within the next one to two years. The deal is in sync with the company's strategy to strengthen its portfolio in its chosen growth markets. This transaction will help the company expand its injectable products portfolio in the U.S. market and globally.

▲ **Biosimilars Market to Boost Revenues:** Dr. Reddy's is working with Merck Serono to develop and commercialize a portfolio of biosimilar compounds in oncology, primarily focused on MABs. Dr. Reddy's has already expanded its biosimilars facility in India to meet growing demand in emerging markets. Dr. Reddy's in July 2018 launched Hervycta (Trastuzumab), a biosimilar of Roche's Herceptin in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer).

▲ **Strategic Initiatives:** The company is undertaking some strategic measures to combat the ongoing challenges. It plans to modernize some of its infrastructure, systematically implement its new quality management system and automate some of the critical manufacturing and quality related processes.

In order to revitalize growth, Dr. Reddy's remains focused on accelerating the development of its complex generics portfolio and also making efforts to ensure that the approvals come in time through appropriate risk management and proactive measures to deal with possible deficiencies.

Dr. Reddy's enjoys a strong position in the generics market. Efforts on strengthening its presence in the biosimilars market have been commendable too.

Reasons To Sell:

- ▼ **Pricing pressure on North America business:** The company's North America base business is witnessing pricing pressures since the last few quarters due to enhanced channel consolidation and increased competitive pressure on sales of some of its key generic products.

In-fact, the United States' generics industry is facing significant competitive and pricing pressure. The ongoing consolidation of customers in the industry has led to increasing price erosion and decreasing volume. The consolidation in the industry has increased the ability to negotiate lower prices for generic drugs. A sharp decline in generic drug prices is proving to be a major challenge for generic drugmakers as well as drug distributors. Moreover, the FDA is speeding up the approval of generic drugs, which means more competition, increasing price cuts and decreasing volume. The pricing and competitive pressures are expected to continue.

The implementation of general sales tax (GST) in India is also hurting its topline to an extent.

- ▼ **Warning Letter for Manufacturing Facilities:** In November 2015, Dr. Reddy's received a warning letter from the FDA regarding a couple of API manufacturing facilities in India as well as its Oncology Formulation manufacturing facility in India. In December 2015, the company submitted a comprehensive, corrective and preventive action plan, to address all the issues raised, which includes manufacturing network and quality/compliance issues. The company has completed its remedial measures and submitted the same as of Mar 2017. The FDA conducted reinspection of the aforementioned manufacturing facilities in March and April 2017. During the re-inspections, the FDA issued three observations with respect to the company's API facility at Miryalaguda, two observations with respect to its API facility at Srikakulam and thirteen observations with respect to its oncology formulation manufacturing facility. With respect to API manufacturing facility at Srikakulam, the company was asked to carry out certain detailed investigations and analyses. The company has completed a portion of this investigation.

In June 2018, the company requested the FDA to schedule a re-inspection of the oncology formulation manufacturing facility at Duvvada. In October 2018, the re-inspection for the injectable plant in Duvvada was completed and the FDA issued eight observations. The company comprehensively responded to this observation and received certain specific questions from the agency, seeking further clarification on some of the company's responses. With respect to the API manufacturing facility in Srikakulam, the company submitted the results of the investigation, and responded to all the queries asked by the FDA. The company is awaiting re-inspection of the facility.

Consequent to this warning letter, the company has been facing a number of challenges that includes price erosion and delay in product launches. These challenges are adversely affecting the company's top-line growth.

- ▼ **Competition in Generics Segment:** The generic market is highly crowded and Dr. Reddy's faces competition from players like Mylan, Teva, Endo and Sandoz among others. Competition is fierce as generic companies strive to be the first to launch a generic version once a brand product loses exclusivity so that they can capture significant market share. Once additional generic companies enter the market, market share, revenues and gross profit typically decline. Therefore, it is very important for generic companies to develop and introduce new products in a timely and cost-effective manner to maintain revenues and gross profit. In addition to competition from other generic players, brand name companies also provide competition by marketing their own generic version (authorized generics) of their brand products.

In December 2019, there was a generic launch and an authorized generic launch for the product, NuvaRing, which has led to a considerable reduction in the valuation of this product for the company.

Persisting macroeconomic issues in some territories in emerging markets and negative impact of a depreciating ruble remain a concern. The FDA warning letter for some manufacturing facilities is also a concern.

Last Earnings Report

Dr. Reddy's Q1 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's reported first-quarter fiscal 2021 earnings of 46 cents per American Depositary Share ("ADS") compared with 53 cents in the year-ago quarter.

Moreover, revenues grew 15% year over year to \$585 million.

While the sales volume were impacted in some of the markets due to lower prescriptions generated and fall in patient footfalls in pharmacies/clinics due to COVID-19, the pricing environment was relatively stable, new product launches continued and depreciation of rupee against the U.S. dollar and Euro supported the business.

Quarter in Detail

Dr. Reddy's reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients ("PSAI"), and Proprietary Products and Others.

Global Generics revenues were INR 35.1 billion (\$464.4 million), up 6% year over year in the fiscal first quarter. Growth was led by contributions from Europe and emerging markets, partially offset by declines in India.

The company launched six products in North America during the reported quarter, including Fenofibrate Tablets, Nitroglycerin Patch, Amphetamine Sulfate Tablets, Desmopressin Acetate Ampules, Colchicine Tablets and Abiraterone Acetate Tablets.

PSAI revenues were INR 8.6 billion (\$113.2 million), up 88% from the year-ago quarter.

Revenues at the Proprietary Products segment came in at INR 0.6 billion, declining 40% year over year due to the absence of the Neurology franchise products (the U.S. and select territory rights of which were sold in the previous year).

Research and development expenses were up 10% year over year to \$53 million. The company is also undertaking the development of a few projects pertaining to COVID-19-related drugs.

Selling, general and administrative expenses were \$169 million, up 6% year over year.

As of June 30, 2020, Dr. Reddy's had 101 generic filings (99 abbreviated New Drug Applications [ANDAs] and two new drug applications) pending FDA approval. Of these 99 ANDAs, 54 were Para IV filings and 28 have first-to-file status.

Quarter Ending 06/2020

Report Date	Jul 29, 2020
Sales Surprise	NA
EPS Surprise	NA
Quarterly EPS	0.46
Annual EPS (TTM)	2.40

Recent News

Launches Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market-Sep 26

Dr. Reddy's announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera (dimethyl fumarate) Delayed-Release Capsules, approved by the FDA.

Tecfidera is a trademark of Biogen.

Launches Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market-Sep 25

Dr. Reddy's announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the FDA.

Precedex is a trademark owned or licensed by of Hospira, Inc.

Launches Olopatadine Hydrochloride Ophthalmic Solution in the U.S. Market-Sep 17

Dr. Reddy's announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store brand equivalents of Pataday Once Daily Relief and Pataday Twice Daily Relief, in the U.S. market, as approved by the FDA.

Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is also indicated for the temporary relief of red eyes.

Pataday is a registered trademark of Novartis AG.

Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers-Sep 17

Dr. Reddy's announced a settlement of its litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb (BMY), relating to patents for Revlimid (lenalidomide) capsules. Revlimid is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with dexamethasone.

Per the settlement, Celgene has agreed to provide Dr. Reddy's with a license to manufacture and sell a limited amount of Revlimid beginning an undisclosed date following March 2022,. The specific volume-limited license date and percentages agreed-upon with Dr. Reddy's were not disclosed and are confidential.

In addition, Celgene has agreed to provide Dr. Reddy's with a license to Celgene's patents required to manufacture and sell an unlimited quantity of generic Revlimid in the United States beginning on Jan 31, 2026.

Launches Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%-Sep 17

Dr. Reddy's announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the storebrand equivalents of Pataday Once Daily Relief and Pataday Twice Daily Relief, in the U.S. market, as approved by the FDA.

Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is also indicated for the temporary relief of red eyes.

RDIF and Dr. Reddy's to Supply of 100 million doses of Sputnik V vaccine-Sep 17

Dr. Reddy's signed a deal with the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, to cooperate on clinical trials and distribution of the Sputnik V vaccine in India. The Sputnik V vaccine, which is based on well studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic. Following regulatory approval in India, RDIF will supply 100 million doses of the vaccine to Dr. Reddy's.

Launches of Over-The-Counter Diclofenac Sodium Topical Gel 1% in U. S. Market-Sep 9

Dr. Reddy's announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren Arthritis Pain in the U.S. market. It is an important addition to the company's Pain/ Analgesics portfolio of OTC products, a

Voltaren is a trademark of Novartis Corporation.

Announces the launch of Redyx in India-Sep 9

Dr. Reddy's announced the launch of Remdesivir, under a brand name Redyx in India. The launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr. Reddy's the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India. Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms. Dr. Reddy's Redyx is available in strength of 100 mg vial.

Launches Fulvestrant Injection in the U.S. Market-Sep 7

Dr. Reddy's announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe, a therapeutic equivalent generic version of Faslodex® (fulvestrant) Injection, 250 mg/5 mL (50 mg/mL), approved by the FDA.

Faslodex is a trademark of the AstraZeneca group of companies.

Launches Methylphenidate Hydrochloride Extended-Release Tablets USP, in U.S. Market-Sep 3

Dr. Reddy's announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a therapeutic equivalent generic version of Concerta (methylphenidate Hydrochloride) Extended-Release Tablets, 18 mg, 27 mg, 36 mg, and 54 mg, approved by the FDA.

Concerta is a trademark owned or licensed by Janssen Pharmaceuticals, Inc.

Announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market-Aug 27

Dr. Reddy's announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the FDA.

Cuprimine is a trademark of Bausch Health Companies Inc.

Enters hospital nutrition segment with Celevida Maxx in India-Aug 25

Dr. Reddy's announced the entry into the hospital nutrition segment with the launch of its nutrition drink, 'Celevida Maxx' in India. It is a unique addition to the Dr. Reddy's nutrition portfolio and is designed to help manage the nutritional needs of Cancer, Critical Care and Chronic Obstructive Pulmonary Disease (COPD) patients in India.

Dr. Reddy's Celevida Maxx contains a unique triple action formula of high protein, high omega 3 fatty acids to help tackle the problem of inflammation and Astaxanthin, which is clinically proven to support immunity.

Celevida Maxx contains vegetarian ingredients, no added sugar and comes in two flavors, Orange and Strawberry

Announces the launch of Avigan (Favipiravir) in India-Aug 19

Dr. Reddy's announced the launch of Avigan (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co. Ltd. that grants Dr. Reddy's the exclusive rights to manufacture, sell and distribute Avigan (Favipiravir) 200 mg Tablets in India. Avigan (Favipiravir) has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease

Announces the First-to-Market launch of the generic version of Ciprodex-Aug 11

Dr. Reddy's announced the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the FDA.

Ciprodex is a trademark of Bayer AG.

Received Approval of Xeglyze Lotion, 0.74%, in the United States-July 27

Dr. Reddy's announced the approval of Xeglyze (abametapir) lotion, 0.74%, NDA by the FDA. The approval triggers the contractual precommercialization milestone of \$20 million payable to Hatchtech Pty Ltd. Xeglyze is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The company is working to commercialize this product through partners. Xeglyze is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.

Launch of Over-The-Counter Nicotine Polacrilex Lozenges in the U.S. Market-July 14

Dr. Reddy's announced the launch of Over-the-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette Lozenges in the U.S. market.

Nicorette is a trademark of GlaxoSmithKline Consumer Healthcare L.P.

Inks Deal With Two Companies for Coronavirus Drug-July 1

Dr. Reddy's partnered with a Japanese pharma giant, FUJIFILM Toyama Chemical (FUJIFILM), and Global Response Aid (GRA) for the development, manufacture and sale of antiviral drug Avigan (favipiravir) tablets for the potential treatment of COVID-19.

The agreement grants Dr. Reddy's exclusive rights for India and both Dr Reddy's and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia. Dr. Reddy's would have exclusive rights for the development, sale and distribution of Avigan in India. Further, FUJIFILM would receive an upfront license fee and royalties on sales from Dr. Reddy's and GRA.

FUJIFILM will provide the data that it has accumulated from Avigan's preclinical and clinical studies to Dr. Reddy's and GRA. The data will then be used by the two companies for studies on COVID-19 where infection has been spreading significantly. Dr. Reddy's will also obtain rights from FUJIFILM to use Avigan's patents of formulation and manufacturing method. Dr. Reddy's will establish a setup for manufacturing drugs of the same quality as Avigan. Further, the company will utilize GRA's global sales network to supply manufactured drugs swiftly and in a stable manner.

Currently, FUJIFILM Group is conducting a study on Avigan targeting COVID-19 patients in Japan and the United States and working to increase the drug's production by partnering with domestic and overseas companies.

Avigan Tablet was developed by FUJIFILM Toyama Chemical and is marketed as an influenza antiviral drug.

Announces the launch of Abiraterone Acetate Tablets USP, 250 mg in US Market-June 19

Dr. Reddy's announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by FDA.

Zytiga is a trademark of Johnson & Johnson corporation.

Inks Deal With Gilead Sciences for Remdesivir-June 13

Dr. Reddy's entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. to register, manufacture and sell the latter's experimental candidate, remdesivir, a potential treatment for COVID-19, in 127 countries including India.

Dr. Reddy's will receive technology transfer from Gilead for manufacturing of this drug. Dr. Reddy's will be responsible for the manufacturing scale-up of the drug and need to obtain regulatory approval for marketing of the same in respective countries.

Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization by the FDA to treat hospitalised patients with severe COVID-19 illness.

Announces the launch of Colchicine Tablets USP 0.6 mg in US Market-June 12

Dr. Reddy's announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcris (colchicine) Tablets, 0.6 mg, approved by the FDA.

Colcris is a trademark of Takeda.

Completes the acquisition of select business divisions of Wockhardt-June 10

Dr. Reddy's announced that it has completed the acquisition of select divisions of Wockhardt Limited's ("Wockhardt") branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives. The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr. Reddy's along with related sales and marketing teams; and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees (together the 'Business Undertaking').

On February 12, 2020, Dr. Reddy's signed a Business Transfer Agreement ('BTA') with Wockhardt, to acquire the above-referred business undertaking for an upfront consideration of Rs.1,850 crores. In view of the COVID-19 pandemic and the consequent government restrictions, there has been a reduction in the revenue from the sales of the products forming part of the Business Undertaking during March & April, 2020. Subsequently, through an amendment to the BTA, Dr. Reddy's and Wockhardt have agreed that the deal consideration shall now be upto Rs. 1,850 crores.

Launch of FXR in Indian Market – May 18

Dr. Reddy's announced the launch of FXR, the therapeutic generic equivalent of Ocaliva (obeticholic acid) in India as a treatment for primary biliary cholangitis, in combination with ursodeoxycholic acid (UDCA) or as monotherapy in adults. FXR is a trademark of Intercept Pharmaceuticals.

Launch of Desmopressin Acetate Injection in the U.S. Market – May 6

Dr. Reddy's announced the launch of Desmopressin Acetate Injection, the therapeutic generic equivalent of DDAVP, approved by the FDA. DDAVP is a trademark of Ferring Pharmaceuticals.

Receives FDA Approval for Elyxib – May 6

Dr. Reddy's announced that the FDA has approved the new drug application seeking approval for Elyxib as acute treatment of migraine with or without aura in adults.

Launch of NitroDur in the U.S. Market – May 6

Dr. Reddy's announced the launch of Desmopressin Acetate Injection, the therapeutic generic equivalent of DDAVP, approved by the FDA. DDAVP is a trademark of Ferring Pharmaceuticals.

Launch of NitroDur in the U.S. Market – Apr 27

Dr. Reddy's announced the launch of Fenofibrate tablets, the therapeutic generic equivalent of Tricor tablets, approved by the FDA. Tricor is a trademark of AbbVie.

Launch of Amphetamine Sulfate Tablets in the U.S. Market – Apr 14

Dr. Reddy's announced the launch of Amphetamine Sulfate tablets, the therapeutic generic equivalent of Evekeo tablets, approved by the FDA. Evekeo is a trademark of Arbor Pharmaceuticals, LLC.

Launch of NitroDur in the U.S. Market – Apr 14

Dr. Reddy's announced the launch of authorized generic version of NitroDur transdermal infusion system, for four dosage strengths —

0.1mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count. NitroDur is a trademark of USpharma Ltd.

Launch of Invista in India – Apr 13

Dr. Reddy's announced the launch of Invista, a formulation of dasatinib that is bioequivalent version of Sprycel. Invista is approved for treating chronic accelerated or myeloid or lymphoid blast phase and newly diagnosed in chronic phase adult patients with Chronic Myeloid Leukemia in India. Sprycel is a trademark of Bristol Myers.

Valuation

Dr. Reddy's shares are up 70.0% in the year-to-date period and up 82.1% over the trailing 12-month period. Stocks in the Zacks sub-industry are down 10.0% and in the Zacks Medical sector are down 1.0%, in the year-to-date period. Over the past year, the Zacks sub-industry is up 8.8% and the sector is up 10.9%.

The S&P 500 index is up 4.1% in the year-to-date period and up 12.8% in the past year.

The stock is currently trading at 33.27X forward 12-month earnings per share, which compares to 7.47X for the Zacks sub-industry, 21.34X for the Zacks sector and 22.77X for the S&P 500 index.

Over the past five years, the stock has traded as high as 35.05X and as low as 16.19X, with a 5-year median of 21.48X. Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$73.00 price target reflects 35.19xforward 12-month earnings per share.

The table below shows summary valuation data for RDY.

Valuation Multiples - RDY					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	33.27	7.47	21.34	22.77
	5-Year High	35.05	11.19	23.19	24.03
	5-Year Low	16.19	5.77	15.89	16.1
	5-Year Median	21.48	7.74	19.02	18.97
P/S F12M	Current	4.38	0.84	2.77	4.09
	5-Year High	4.55	2.66	3.25	4.3
	5-Year Low	1.79	0.72	2.24	3.11
	5-Year Median	2.67	1.2	2.89	3.66
P/B TTM	Current	5.34	1.1	3.88	5.77
	5-Year High	6.23	2.96	5.07	6.19
	5-Year Low	2.43	0.73	2.95	3.75
	5-Year Median	3.39	1.26	4.29	4.86

As of 09/28/2020

Source: Zacks Investment Research

Industry Analysis Zacks Industry Rank: Bottom 12% (219 out of 250)



Source: Zacks Investment Research

Top Peers

Company (Ticker)	Rec	Rank
Bausch Health Cos Inc. (BHC)	Neutral	3
Endo International plc (ENDP)	Neutral	4
GlaxoSmithKline plc (GSK)	Neutral	3
Mallinckrodt public limited company (MNK)	Neutral	3
Mylan N.V. (MYL)	Neutral	3
Novartis AG (NVS)	Neutral	3
Sanofi (SNY)	Neutral	3
Teva Pharmaceutical Industries Ltd. (TEVA)	Neutral	3

The positions listed should not be deemed a recommendation to buy, hold or sell.

Industry Comparison Industry: Medical - Generic Drugs				Industry Peers		
	RDY	X Industry	S&P 500	MYL	NVS	TEVA
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	2	-	-	3	3	3
VGM Score	C	-	-	B	B	D
Market Cap	11.44 B	391.57 M	23.11 B	7.57 B	199.23 B	9.61 B
# of Analysts	1	4	14	8	5	9
Dividend Yield	0.40%	0.00%	1.66%	0.00%	2.31%	0.00%
Value Score	C	-	-	A	B	A
Cash/Price	0.03	0.35	0.08	0.04	0.03	0.25
EV/EBITDA	26.75	-2.15	13.15	6.37	14.03	69.64
PEG F1	NA	1.30	2.88	1.96	1.83	0.64
P/B	5.34	2.39	3.29	0.64	3.70	0.65
P/CF	18.19	2.26	12.83	1.76	11.02	2.26
P/E F1	36.08	4.22	21.32	3.30	15.24	3.54
P/S TTM	4.64	1.80	2.49	0.66	4.13	0.57
Earnings Yield	2.75%	-10.36%	4.44%	30.33%	6.56%	28.30%
Debt/Equity	0.04	0.00	0.70	0.84	0.48	1.66
Cash Flow (\$/share)	3.79	-0.31	6.92	8.33	7.90	3.89
Growth Score	B	-	-	C	B	F
Historical EPS Growth (3-5 Years)	9.95%	1.65%	10.43%	0.16%	2.64%	-19.63%
Projected EPS Growth (F1/F0)	-31.90%	-7.19%	-4.22%	0.40%	9.01%	3.57%
Current Cash Flow Growth	40.31%	0.54%	5.47%	-3.91%	4.27%	-9.67%
Historical Cash Flow Growth (3-5 Years)	5.28%	7.89%	8.52%	16.74%	7.11%	-6.21%
Current Ratio	1.66	2.34	1.35	0.93	0.81	1.09
Debt/Capital	4.03%	0.25%	42.91%	45.72%	32.25%	62.41%
Net Margin	10.26%	-48.59%	10.28%	2.35%	14.96%	0.03%
Return on Equity	18.88%	-40.26%	14.73%	20.43%	24.14%	17.88%
Sales/Assets	0.77	0.36	0.50	0.38	0.40	0.30
Projected Sales Growth (F1/F0)	1.95%	1.45%	-1.38%	3.66%	5.28%	-3.73%
Momentum Score	D	-	-	D	D	F
Daily Price Change	-0.85%	0.00%	1.85%	1.53%	-0.07%	0.92%
1-Week Price Change	-3.88%	-6.48%	-2.32%	-8.33%	-4.21%	-8.02%
4-Week Price Change	18.64%	-8.65%	-2.53%	-10.62%	1.15%	-10.84%
12-Week Price Change	31.90%	-13.50%	4.17%	-11.49%	-1.59%	-23.61%
52-Week Price Change	82.13%	-11.67%	0.12%	-25.99%	0.17%	27.91%
20-Day Average Volume (Shares)	192,199	270,843	2,098,704	5,563,759	1,785,645	7,402,651
EPS F1 Estimate 1-Week Change	0.00%	0.00%	0.00%	0.00%	-0.17%	0.00%
EPS F1 Estimate 4-Week Change	-1.30%	0.00%	0.00%	0.00%	-0.10%	-0.10%
EPS F1 Estimate 12-Week Change	3.54%	0.24%	4.22%	2.22%	1.17%	0.30%
EPS Q1 Estimate Monthly Change	NA%	0.00%	0.00%	0.00%	2.92%	-0.27%

Source: Zacks Investment Research

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we maintain a balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	C
Growth Score	B
Momentum Score	D
VGM Score	C

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.

Additional Disclosure

This material represents an assessment of the market and economic environment at a specific point in time and is not intended to be a forecast of future events, or a guarantee of future results. Forward-looking statements are subject to certain risks and uncertainties. Any statements that refer to expectations, projections or characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Actual results, performance, or achievements may differ materially from those expressed or implied.

Returns quoted represent past performance which is no guarantee of future results. Investment returns and principal value will fluctuate so that when shares are redeemed, they may be worth more or less than their original cost. Current performance may be higher or lower than the performance shown.

Investing involves risk; principal loss is possible. There is no guarantee that companies that can issue dividends will declare, continue to pay or increase dividends.

Glossary of Terms and Definitions

52-Week High-Low: The range of the highest and lowest prices at which a stock has traded during the past year. This range is determined based on the stock's daily closing price which may differ from the intra-day high or low. Many investors use it as a technical indicator to determine a stock's current value and future price movement. The idea here is that if price breaks out from the 52-week range, in either direction, the momentum may continue in the same direction.

20-Day Average Volume (Shares): The average number of shares of a company traded in a day over the last 20 days. It is a direct indication of a security's overall liquidity. The higher the average daily trading volume, the easier it is to enter or exit the stock at a desired price with more buyers and sellers being available.

Daily Price Change: This is the percentage difference between a trading day's closing price and the prior trading day's closing price. This item is updated at 9 p.m. EST each day.

1-Week Price Change: This is the percentage change in a stock's closing price over the last 5 trading days. This change reflects the collective buying and selling sentiment over the 1-week period.

A strong weekly price increase for the stock, especially when accompanied by increased volume, is an indication of it gaining momentum.

4-Week Price Change: This is the percentage change in a stock's closing price over the last 20 trading days or past 4 weeks. This is a medium-term price change metric and an indication of the stock gaining momentum.

12-Week Price Change: This is the percentage change of a stock's closing price over the last 60 trading days or past 12 weeks. Similar to 4-week price change, this is a medium-term price change metric. It shows whether a stock has been enjoying strong investor demand, or if it has been in consolidation, or distress over this period.

52-Week Price Change: This is the percentage change in a stock's closing price over the last 260 trading days or past 52 weeks. This long-term price change metric is a good reference point for investors. Some investors seek stocks with the best percentage price change over the last 52 weeks, expecting the momentum to continue.

Market Cap: The number of outstanding common shares of a company times its latest price per share. This figure represents a company's size, which indicates various characteristics, including price stability and risk, in which investors could be interested.

Year-To-Date Price Change: Change in a stock's daily closing price in the period of time beginning the first day of the current calendar year through to the previous trading day.

of Analysts: Number of EPS estimates used in calculating the current-quarter consensus. These estimates come from the brokerage analysts tracking this stock. However, the number of such analysts tracking this stock may not match the number of estimates, as all brokerage analysts may not come up with an estimate or provide it to us.

Beta: A measure of risk commonly used to compare the volatility of a stock to the overall market. The S&P 500 Index is the base for calculating beta and carries a value of 1. A stock with beta below 1 is less risky than the market as a whole. And a stock with beta above 1 is riskier.

Dividend: The portion of earnings a company is expected to distribute to its common shareholders in the next 12 months for each share they own. Dividends are usually paid quarterly. Dividend payments reflect positively on a company and help maintain investors' trust. Investors typically find dividend-paying stocks appealing because the dividend adds to any market price appreciation to result in higher return on investment (ROI). Moreover, a steady or increasing dividend payment provides investors a cushion in a down market.

Dividend Yield: The ratio of a company's annual dividend to its share price. The annual dividend used in the ratio is calculated based on the most recent dividend paid by the company. Dividend yield is an estimate of the dividend-only return from a stock in the next 12 months. Since dividend itself doesn't change frequently, dividend yield usually changes with a stock's price movement. As a result, often an unusually high dividend yield is a result of weak stock price.

S&P 500 Index: The Standard & Poor's 500 (S&P 500) Index is an unmanaged group of securities considered to be representative of the stock market in general. It is a market-capitalization-weighted index of stocks of the 500 largest U.S. companies. Each stock's weight in the index is proportionate to its market value.

Industry: One of the 250+ groups that Zacks classifies all stocks into based on the nature of business. These groups are termed as expanded (aka "X") industries and map to their respective (economic) sectors; Zacks has 16 sectors.

Zacks Industry Rank: The Zacks Industry Rank is determined by calculating the average Zacks Rank for all stocks in the industry and then assigning an ordinal rank to it. For example, an industry with an average Zacks Rank of 1.6 is better than an industry with an average Zacks Rank of 2.3. So, the industry with the better average Zacks Rank would get a better Zacks Industry Rank. If an industry has the best average Zacks Rank, it would be considered the top industry (1 out of 250+), which would place it at the top 1% of Zacks-ranked industries. Studies have shown that roughly half of a stock's price movement can be attributed to the industry group it belongs to. In fact, the top 50% of Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.

Last EPS Surprise: The percentage deviation of a company's last reported earnings per share from the Zacks Consensus Estimate. Companies with a positive earnings surprise are more likely to surprise again in the future (or miss again if they recently missed).

Last Sales Surprise: The percentage deviation of a company's last reported sales from the Zacks Consensus Estimate.

Expected Report Date: This is an estimated date of a company's next earnings release. The information originated or gathered by Zacks Investment Research from its information providers or publicly available sources is the basis of this estimate.

Earnings ESP: The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the yet-to-be reported quarter. The Most Accurate Estimate is the most recent version of the Zacks Consensus EPS Estimate. The idea here is that analysts revising their estimates closer to an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time.

Periods:

TTM: Trailing 12 months. Using TTM figures is an effective way of analyzing the most-recent financial data in an annualized format that helps neutralize the effects of seasonality and other quarter-to-quarter variation.

F1: Current fiscal year. This period is used to analyze the estimates for the ongoing full fiscal year.

F2: Next fiscal year. This period is used to analyze the estimates for the next full fiscal year.

F12M: Forward 12 months. Using F12M figures is an effective way of analyzing the near-term (the following four unreported quarters) estimates in an annualized manner. Instead of typically representing estimates for the full fiscal year, which may not represent the nitty-gritty of each quarter, F12M figures suggest an all-inclusive annualized estimate for the following four quarters. The annualization helps neutralize the potential effects of seasonality and other quarter-to-quarter variations.

P/E Ratio: The price-to-earnings ratio measures a company's current market price per share relative to its earnings per share (EPS). Usually, the trailing-12-month (TTM) EPS, current-fiscal-year (F1) EPS estimate, or forward-12-month (F12M) EPS estimate is used as the denominator. In essence, this ratio shows what the market is willing to pay today for each dollar of EPS. In other words, this ratio gives a sense of what the relative value of the company is at the already reported level of earnings or at a future level of earnings.

It is one of the most widely-used multiples for determining the value of a company and helps comparing its valuation with that of a competitor, the industry group or a benchmark.

PEG Ratio: The price/earnings to growth ratio is a stock's P/E ratio using current fiscal year (F1) EPS estimate divided by its expected EPS growth rate over the coming 3 to 5 years. This ratio essentially determines a stock's value by factoring in the company's expected earnings growth and is thus believed to provide a more complete picture than just the P/E ratio, particularly for faster-growing companies.

P/S Ratio: The price-to-sales ratio is calculated as a company's current price per share divided by trailing 12 months (TTM) sales or revenues per share. This ratio shows what the market is willing to pay today for each dollar of TTM sales per share. The P/S ratio is at times the only valuation metric when the company has yet to become profitable.

Cash/Price Ratio: The cash-to-price ratio or Cash Yield is calculated as cash and marketable securities per share divided by the company's current share price. Like the earnings yield, which shows the anticipated yield (or return) on a stock from earnings for each dollar invested, the cash yield does the same, with cash being the source of return instead of earnings. For example, a cash/price ratio of 0.08 suggests a return of 8% or 8 cents for every \$1 investment.

EV/EBITDA Ratio: The EV/EBITDA ratio, also known as Enterprise Multiple, is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by EBITDA (earnings before interest, taxes, depreciation and amortization). Usually, trailing-12-month (TTM) or forward-12-month (F12M) EBITDA is used as the denominator.

EV/Sales Ratio: The enterprise value-to-sales ratio is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by annual sales. It is an expansion of the P/S valuation, which uses market value instead of enterprise value. The EV/Sales ratio is perceived as more accurate than P/S, in part, because the market capitalization does not take a company's debt into account when valuing it.

EV/CF Ratio: The enterprise value-to-cash flow ratio is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by the trailing-12-month (TTM) operating cash flow. It's a measure of how long it would take to buy the entire business if you were able to use all the company's operating cash flow.

The EV/CF ratio is perceived as more accurate than the P/CF ratio, in part, because the market price does not take a company's debt into account when valuing it.

EV/FCF Ratio: The enterprise value-to-free cash flow metric compares a company's enterprise value to its trailing-12-month (TTM) free cash flow (FCF). This metric is very similar to the EV/CF ratio, but is considered a more exact measure owing to the fact that it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available for funding growth activities and payments to shareholders.

P/EBITDA Ratio: The P/EBITDA ratio is calculated as a company's per share market value divided by EBITDA (earnings before interest, taxes, depreciation, and amortization). This metric is very similar to the EV/EBITDA ratio, but is considered a little less exact measure as it uses market price, which does not take a company's debt into account. However, since EBITDA is often considered a proxy for cash income, the metric is used as a measure of what the market is willing to pay today for each dollar of the company's cash profitability in the trailing 12 months (TTM) or forward 12 months (F12M).

P/B Ratio: The price-to-book ratio is calculated as a company's current price per share divided by its book value (total assets – liabilities – preferred stocks) per share. In short, the book value is how much a company is worth. In other words, it reflects the total value of a company's assets that its common shareholders would receive if it were to be liquidated. So, the P/B ratio indicates whether you're paying higher or lower than what would remain if the company went bankrupt immediately. Investors typically use this metric to determine how a company's stock price stacks up to its intrinsic value.

P/TB Ratio: The price-to-tangible-book value ratio is calculated as a the per share market value of a company divided by the value of its tangible assets (total assets – liabilities – preferred stocks – intangible assets) per share. Tangible book value is the same thing as book value except it excludes the value of intangible assets to get a step closer to the baseline value of the company.

P/CF Ratio: The price-to-cash flow ratio measures a company's per share market price relative to its trailing-12-month (TTM) operating cash flow per share. This metric is used to determine whether a company is undervalued or overvalued relative to another stock, industry or sector. And like the P/E ratio, a lower number is typically considered better from the value perspective.

One of the reasons why P/CF ratio is often preferred over P/E ratio is the fact that operating cash flow adds back non-cash expenses such as depreciation and amortization to net income. This feature helps valuing stocks that have positive cash flow but are not profitable because of large noncash charges.

P/FCF Ratio: The price-to-free cash flow ratio is an extension of P/CF ratio, which uses trailing-12-month (TTM) free cash flow per share instead of operating cash flow per share. This metric is considered a more exact measure than P/CF ratio, as free cash flow subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available for funding activities that generate additional revenues.

Earnings Yield: The earnings yield is calculated as current fiscal year (F1) EPS estimate divided by the company's current share price. The ratio, which is the inverse of the P/E ratio, measures the anticipated yield (or return) from earnings for each dollar invested in a stock today.

For example, earnings yield for a stock, which is trading at \$35 and expected to earn \$3 per share in the current fiscal year (F1), would be 0.0857 ($3/35 = 0.0857$) or 8.57%. In other words, for \$1 invested in the stock today, the yield from earnings is anticipated to be 8.57 cents.

Investors most commonly compare the earnings yield of a stock to that of a broad market index (such as the S&P 500) and prevailing interest rates, such as the current 10-year Treasury yield. Since bonds and stocks compete for investors' dollars, stock investors typically demand a higher yield for the extra risk they assume compared to investors of U.S. Treasury-backed securities that offer virtually risk-free returns. This additional return is referred to as the risk premium.

Debt/Equity Ratio: The debt-to-equity ratio is calculated as a company's total liabilities divided by its shareholder equity. This metric is used to gauge a company's financial leverage. In other words, it is a measure of the degree to which a company is financing its operations through debt versus its own funds. The higher the ratio, the higher the risk for shareholders.

However, this ratio is difficult to compare across industry groups where ideal amounts of debt vary. Some businesses are more capital intensive than others and typically require higher debt to finance their operations. So, a company's debt-to-equity ratio should be compared with other companies in the same industry.

Cash Flow (\$/share): Cash flow per share is calculated as operating cash flow (after-tax earnings + depreciation + other non-cash charges) divided by common shares outstanding. It is used by many investors as a measure of a company's financial strength. Since cash flow per share takes into consideration a company's ability to generate cash by adding back non-cash expenses, it is regarded by some as a more accurate measure of a company's financial situation than earnings per share, which could be artificially deflated.

Current Ratio: The current ratio or liquidity ratio is a company's current assets divided by its current liabilities. It measures a company's ability to pay short-term obligations. A current ratio that is in line with the industry average or slightly higher is generally considered acceptable. A current ratio that is lower than the industry average would indicate a higher risk of distress or default. A higher number is usually better. However, a very high current ratio compared to the industry average could be an indication of inefficient use of assets by management.

Debt/Capital Ratio: Debt-to-capital ratio is a company's total debt (interest-bearing debt + both short- and long-term liabilities) divided its total capital (interest-bearing debt + shareholders' equity). It is a measure of a company's financial leverage. All else being equal, the higher the debt-to-capital ratio, the riskier the stock.

However, this ratio can vary widely from industry to industry, the ideal amount of required debt being different. Some businesses are more capital intensive than others and typically require higher debt to finance their operations. So, a company's debt-to-capital ratio should be compared with the same for its industry.

Net Margin: Net margin is calculated as net income divided by sales. It shows how much of each dollar in sales generated by a company translates into profit. For example, if a company's net margin is 15%, its net income is 15 cents for every \$1 of sales it makes.

A change in margin can reflect either a change in business conditions, or a company's cost controls, or both. If a company's expenses are growing faster than sales, its net margin will decline. However, different net margin rates are considered good for different industries, so it's better to compare net margin rates of companies in the same industry group.

Return on Equity: Return on equity (ROE) is calculated as trailing-12-month net income divided by trailing-12-month average shareholder equity (including reinvested earnings). This metric is considered a measure of how effectively management is using a company's assets to generate profits. For example, if a company's ROE is 10%, it creates 10 cents profits for every \$1 shareholder equity, which is basically the company's assets minus debt. A company's ROE deemed good or bad depends on what's normal for its peers or industry group.

Sales/Assets Ratio: The sales-to-assets ratio or asset utilization ratio or asset turnover ratio is calculated as a company's annual sales divided by average assets (average of assets at the beginning of the year and at the year's end). This metric helps investors understand how effectively a company is using its assets to generate sales. For example, a sales-to-assets ratio of 2.5 indicates that the company generated \$2.50 in sales for every \$1 of assets on its books.

The higher the sales-to-assets ratio, the better the company is performing. However, similar to many other ratios, the asset turnover ratio tends to be higher for companies in certain industries/sectors than in others. So, a company's sales-to-assets ratio should be compared with the same for its industry/sector.

Historical EPS Growth (3-5 Years): This is the average annual (trailing-12-month) EPS growth rate over the last 3-5 years. This metric helps investors see how a company's EPS has grown from a long-term perspective.

Note: There are many factors that can influence short-term numbers — a recession will reduce this number, while a recovery will inflate it. The longterm perspective helps smooth out short-term events.

Projected EPS Growth (F1/F0): This is the estimated EPS growth rate for the current financial year. It is calculated as the consensus estimate for the current fiscal year (F1) divided by the reported EPS for the last completed fiscal year (F0).

Current Cash Flow Growth: It measures the latest year-over-year change in operating cash flow. Cash flow growth tells an investor how quickly a company is generating inflows of cash from operations. A positive change in the cash flow is desired and shows that more 'cash' is coming in than going out.

Historical Cash Flow Growth (3-5 Years): This is the annualized change in cash flow over the last 3-5 years. The change in a longer period helps put the current reading into proper perspective. By looking at the rate, rather than the actual dollar value, the comparison across the industry and peers becomes easier.

Projected Sales Growth (F1/F0): This metric looks at the estimated sales growth for the current year. It is calculated as sales estimate for the current fiscal year (F1) divided by the reported sales for the last completed fiscal year (F0).

Like EPS growth, a higher rate is better for sales growth. A look at a company's projected sales growth instantly tells you what the outlook is for their products and services. However, different sales growth rates are considered good for different industries, so it's better to compare sales growth rates of companies in the same industry group.

EPS F1 Estimate 1-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past week. The change in a company's consensus EPS estimate (or earnings estimate revision) has proven to be strongly correlated with the near-term price movement of its shares. It is an integral part of the Zacks Rank.

If a stock's consensus EPS estimate is \$1.10 now versus \$1.00 a week ago, that will be reflected as a 10% upward revision. If, on the other hand, it went from \$1.00 to 90 cents, that would be a 10% downward revision.

EPS F1 Estimate 4-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past four weeks.

A stock's earnings estimate revision in a 1-week period is important. But it's more meaningful to look at the longer-term revision. And, of course, the 4-week change helps put the 1-week change into proper perspective.

EPS F1 Estimate 12-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past 12 weeks.

This metric essentially shows how the consensus EPS estimate has changed over a period longer than 1 week or 4 weeks.

EPS Q1 Estimate Monthly Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal quarter over the past four weeks.

While the revision in consensus EPS estimate for the current fiscal year is strongly correlated with the near-term price movement of its shares, the estimate revision for the current fiscal quarter is an important metric as well, especially over the short term, and particularly as a stock approaches its earnings date. If a stock's Q1 EPS estimate decreases ahead of its earnings release, it's usually a negative sign, whereas an increase is a positive sign.